For years, companies have offered remote data entry systems to transfer data from trial sites to a central server. But Big Pharma has by and large stuck to its old-fashioned paper ways. Now several start-ups are offering a new breed of web-based RDE and the pharmaceutical industry is starting to take interest. But before embracing an online approach to data collection, drug companies want proof that doing so will save them time and money. Pharma companies must also evaluate how to integrate data collection and management into the rest of their infrastructures. Collaboration rather than competition might best enable pharmaceutical; companies to fully realize the benefits of web-enabled trials through the cooperative sharing of resources.
by Jeffrey Dvorin
For an industry so dependent on technological innovation on the front end of R&D, Big Pharma has been remarkably slow in applying new technologies to the clinical phase of drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
